Sera Prognostics, Inc. (NASDAQ: SERA)

Sera Prognostics, Inc., a company that trades under the symbol SERA, operates in the women's health industry. The company's primary business activities involve the utilization of a proprietary proteomics and bioinformatics platform to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests and predictive analytic products and services. Sera Prognostics operates in a significant and growing market, with a focus on providing deep characterization of the biology of pregnancy, which enables the development of clinically meaningful and economically impactful predictions for pregnancy outcomes.

The company generates revenue through the development and commercialization of its biomarker tests and predictive analytic products and services. Its primary product is the PreTRM test, which is the only broadly validated, commercially available blood test proven to predict the risk of an individual woman delivering prematurely. The PreTRM test combines the ratio of insulin-like growth factor-binding protein 4, or IBP4, to sex hormone-binding globulin, or SHBG, with a woman's height and weight to predict the risk of spontaneous preterm birth. The test has been rigorously validated in multiple maternal fetal medicine centers located in the United States, Europe, Asia, and Africa.

Sera Prognostics has a strong position within the industry, with a proprietary technology platform that is designed to provide deep characterization of the biology of pregnancy. The company's platform has been validated through rigorous clinical trials and has been shown to be effective in predicting the risk of preterm birth. The company is also developing a pipeline of novel blood-based biomarker tests for a number of major pregnancy-related conditions beyond preterm birth, including preeclampsia, fetal growth restriction, gestational diabetes mellitus, stillbirth, and postpartum depression.

The company's customers include healthcare providers, payers, and employers. Its products and services are designed to provide pregnant women and their healthcare providers with more timely and actionable information on pregnancy outcomes, which can enable more effective management of pregnancy and improve the health of mothers and babies.